4-[(7-methoxy-2,4(1H,3H)-quinazolinedione-3-yl)sulfonyl]anthranilic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(7-methoxy-2,4(1H,3H)-quinazolinedione-3-yl)sulfonyl]anthranilic acid
• 英文别名: 4-[(7-methoxy-2.4 (1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic Acid；4-[(7-Methoxy-2,4(1H,3H)-Quinazolinedion-3-yl)Sulfonyl]Anthranilic Acid；2-amino-4-[(7-methoxy-2,4-dioxo-1H-quinazolin-3-yl)sulfonyl]benzoic acid
• 化学式: C₁₆H₁₃N₃O₇S
• 分子量: 391.361
• InChiKey: IMOORYFTTXSOQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  165
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  tert-butyl 4-aminosulfonyl-2-((benzyloxycarbonyl)amino)benzoate 、 benzyl 4-methoxy-2-N-phenoxycarbonylanthranilate 以to obtain 15 mg (yield 3.1%: 4 steps) of the above-identified compound的产率得到4-[(7-methoxy-2,4(1H,3H)-quinazolinedione-3-yl)sulfonyl]anthranilic acid
  参考文献：
  名称：

  Preventive or therapeutic drugs for various eosinophilia-related diseases containg chymase inhibitors as the active ingredient

  摘要：

  一种药物，用于预防或治疗涉及增加嗜酸性粒细胞的疾病，其有效成分为一种具有抑制蛋白酶的药物，是一种安全的药物，可用于预防或治疗伴随嗜酸性粒细胞增多的疾病，抑制病情的进展，预防并发症的进展，改善患者的生活质量，其中包括具有以下公式（I）的喹唑啉衍生物或其药学上可接受的盐：1。

  公开号：

  US20020187989A1

文献信息

• PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT
  申请人：——

  公开号：US20020183338A1

  公开（公告）日：2002-12-05

  A medicament for the prevention or treatment containing a chymase inhibitor, as an effective component, which is a side effect-free, safe medicament for prevention or treatment of fibrosis of the skin or various viscera which suppresses the progression of the condition, prevents the progression of complications, and improves the quality of life of the patient, wherein a quinazoline derivative having the formula (I): 1 or a pharmaceutically acceptable salt thereof is included therein.

  一种预防或治疗皮肤或各种内脏纤维化的药物，含有一种作为有效成分的针对钠胃蛋白酶抑制剂，是一种无副作用、安全的药物，可抑制病情的进展，预防并改善并发症的发展，并提高患者的生活质量，其中包括具有以下结构式(I)的喹唑啉衍生物或其药用盐。
• Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient
  申请人：——

  公开号：US20020183339A1

  公开（公告）日：2002-12-05

  A medicament safe and free from side effects, for the prevention or treatment of dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen, which suppresses the progress of the condition and improves the quality of life of the patient, which medicament treats dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen by including a quiazoline derivative having the formula (I) or (II) or its pharmaceutically acceptable salt as an effective ingredient: 1

  一种安全且没有副作用的药物，用于预防或治疗表现为双相炎症反应的皮炎或由重复接触抗原引起的皮炎，该药物抑制该病情的进展并改善患者的生活质量，该药物通过包括具有公式（I）或（II）的喹唑啉衍生物或其药学上可接受的盐作为有效成分来治疗表现为双相炎症反应的皮炎或由重复接触抗原引起的皮炎：1
• METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR
  申请人：Fukami Harukazu

  公开号：US20100029695A1

  公开（公告）日：2010-02-04

  A medicament safe and free from side effects, for the prevention or treatment of dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen, which suppresses the progress of the condition and improves the quality of life of the patient, which medicament treats dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen by including a quiazoline derivative having the formula (I) or (II) or its pharmaceutically acceptable salt as an effective ingredient:

  一种安全且无副作用的药物，用于预防或治疗表现为双相炎症反应的皮炎或由重复接触抗原引起的皮炎，该药物抑制疾病的进展并改善患者的生活质量。该药物通过将具有公式（I）或（II）的喹唑啉衍生物或其药学上可接受的盐作为有效成分来治疗表现为双相炎症反应的皮炎或由重复接触抗原引起的皮炎。
• Quinazoline derivatives and pharmaceutical applications thereof
  申请人：Fukami Harukazu

  公开号：US06867214B1

  公开（公告）日：2005-03-15

  A quinazoline derivative having formula (1) and a pharmaceutically acceptable salt thereof: wherein the ring A represents an aryl group, which derivative has a chymase inhibitory activity and suppresses the exacerbation of vascular permeability induced by chymase, and a pharmaceutical composition containing the same as an essential ingredient. These compounds are useful for treatment of allergic diseases, rheumatic diseases, and cardiac and circulatory system diseases which are due to the abnormal exacerbation of Angiotensin II production.

  具有以下式子（1）和其药学上可接受的盐的喹唑啉衍生物：其中，环A代表芳基基团，该衍生物具有抑制chymase活性和抑制由chymase诱导的血管通透性加剧的作用，并且包含该衍生物作为必要成分的制药组合物。这些化合物对于治疗由Angiotensin II产生异常加剧引起的过敏性疾病、风湿性疾病以及心脏和循环系统疾病非常有用。
• Chymase inhibitor for the treatment of eosinophilia
  申请人：Daiichi Suntory Pharma Co., Ltd.

  公开号：US06677344B2

  公开（公告）日：2004-01-13

  A chymase inhibitor for the prevention or treatment of diseases involving an increase of eosinophils, as the effective ingredient, is disclosed, suppress the progress of the disease and to prevent progression of complications, wherein the chymase inhibitor is a quinazoline derivative having the formula (I): wherein X, R1, R2 and R3 are herein defined, or a pharmaceutically acceptable salt thereof.

  本发明揭示了一种以chymase抑制剂作为有效成分，用于预防或治疗涉及嗜酸性粒细胞增多的疾病，抑制疾病进展并预防并发症进展的药物，其中所述的chymase抑制剂是具有式(I)的喹唑啉衍生物，其中X、R1、R2和R3在此定义，或其药学上可接受的盐。